Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2005 6
2006 1
2007 4
2008 2
2009 7
2010 4
2011 5
2012 9
2013 7
2014 4
2015 7
2016 7
2017 12
2018 12
2019 7
2020 13
2021 15
2022 18
2023 11
2024 22
2025 22
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

185 results

Results by year

Filters applied: . Clear all
Page 1
2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP).
Banach M, Reiner Ž, Surma S, Bajraktari G, Bielecka-Dabrowa A, Bunc M, Bytyçi I, Ceska R, Cicero AFG, Dudek D, Dyrbuś K, Fedacko J, Fras Z, Gaita D, Gavish D, Gierlotka M, Gil R, Gouni-Berthold I, Jankowski P, Járai Z, Jóźwiak J, Katsiki N, Latkovskis G, Magda SL, Margetic E, Margoczy R, Mitchenko O, Durak-Nalbantic A, Ostadal P, Paragh G, Petrulioniene Z, Paneni F, Pećin I, Pella D, Postadzhiyan A, Stoian AP, Trbusic M, Udroiu CA, Viigimaa M, Vinereanu D, Vlachopoulos C, Vrablik M, Vulic D, Penson PE; International Lipid Expert Panel (ILEP). Banach M, et al. Among authors: gil r. Drugs. 2024 Dec;84(12):1541-1577. doi: 10.1007/s40265-024-02105-5. Epub 2024 Nov 4. Drugs. 2024. PMID: 39497020 Free PMC article.
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity and mortality across Europe. ...In addition to statins, which have been available for several decades, ezetimibe, bempedoic acid (also as …
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidit …
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators; Freij A, Thorsén M. Wallentin L, et al. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30. N Engl J Med. 2009. PMID: 19717846 Free article. Clinical Trial.
METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admi …
METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and …
European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics.
Timmis A, Aboyans V, Vardas P, Townsend N, Torbica A, Kavousi M, Boriani G, Huculeci R, Kazakiewicz D, Scherr D, Karagiannidis E, Cvijic M, Kapłon-Cieślicka A, Ignatiuk B, Raatikainen P, De Smedt D, Wood A, Dudek D, Van Belle E, Weidinger F; ESC National Cardiac Societies. Timmis A, et al. Eur Heart J. 2024 Oct 7;45(38):4019-4062. doi: 10.1093/eurheartj/ehae466. Eur Heart J. 2024. PMID: 39189413 Free article.
This report from the European Society of Cardiology (ESC) Atlas Project updates and expands upon the 2021 report in presenting cardiovascular disease (CVD) statistics for the ESC member countries. This paper examines inequalities in cardiovascular healthcare and out …
This report from the European Society of Cardiology (ESC) Atlas Project updates and expands upon the 2021 report in presenting cardiovasc …
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, Džavík V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta SR, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM. Mehran R, et al. Among authors: gil r. N Engl J Med. 2019 Nov 21;381(21):2032-2042. doi: 10.1056/NEJMoa1908419. Epub 2019 Sep 26. N Engl J Med. 2019. PMID: 31556978 Clinical Trial.
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B; SOCRATES-REDUCED Investigators and Coordinators. Gheorghiade M, et al. JAMA. 2015 Dec 1;314(21):2251-62. doi: 10.1001/jama.2015.15734. JAMA. 2015. PMID: 26547357 Clinical Trial.
Genetic testing for inherited cardiovascular diseases. A position statement of the Polish Cardiac Society endorsed by Polish Society of Human Genetics and Cardiovascular Patient Communities.
Biernacka EK, Osadnik T, Bilińska ZT, Krawczyński M, Latos-Bieleńska A, Łaczmańska I, Miszczak-Knecht M, Płoski R, Ponińska JK, Prejbisz A, Rubiś P, Rudnicka A, Szczałuba K, Szczygieł JA, Własienko P, Wołczenko A, Zienciuk-Krajka A, Ziółkowska L, Gil R. Biernacka EK, et al. Among authors: gil r. Kardiol Pol. 2024;82(5):569-593. doi: 10.33963/v.phj.100490. Epub 2024 May 7. Kardiol Pol. 2024. PMID: 38712785 Free article.
According to the latest guidelines of European and American medical societies, genetic testing (GT) is essential in cardiovascular diseases for establishing diagnosis, predicting prognosis, enabling initiation of disease-modifying therapy, and preventing sudden cardiac dea …
According to the latest guidelines of European and American medical societies, genetic testing (GT) is essential in cardiovascular di …
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators. Schwartz GG, et al. N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5. N Engl J Med. 2012. PMID: 23126252 Free article. Clinical Trial.
However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain. Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes. ...CONCLUSIONS: …
However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain. Inhibition of choleste …
Artificial Intelligence based fractional flow reserve.
Bednarek A, Gąsior P, Jaguszewski M, Buszman PP, Milewski K, Hawranek M, Gil R, Wojakowski W, Kochman J, Tomaniak M. Bednarek A, et al. Among authors: gil r. Cardiol J. 2025;32(5):487-504. doi: 10.5603/cj.102635. Epub 2025 Aug 14. Cardiol J. 2025. PMID: 40810307 Free PMC article. Review.
European Society of Cardiology: cardiovascular disease statistics 2025.
Timmis A, Petersen SE, Van Belle E, Townsend N, Conrad N, Kaplon-Cieslicka A, Kazakiewicz D, Kavousi M, Cvijic M, Ignatiuk B, Torbica A, Scherr D, Boriani G, Chieffo A, Karagiannidis E, Price S, Puererfellner H, Wood A, Lüscher TF, Vardas PE; ESC Public Health Department; ESC National Cardiac Societies. Timmis A, et al. Eur Heart J. 2026 Jul 14;47(27):3499-3543. doi: 10.1093/eurheartj/ehag345. Eur Heart J. 2026. PMID: 42150766 Free article.
This 2025 report from the ESC Atlas project is the fifth in a biennial series. It presents and compares updated cardiovascular disease (CVD) statistics for more than 50 of the ESC member countries. The statistics are for 2024 or latest available year and are stratified by …
This 2025 report from the ESC Atlas project is the fifth in a biennial series. It presents and compares updated cardiovascular diseas …
Gene Variants Related to Cardiovascular and Pulmonary Diseases May Correlate with Severe Outcome of COVID-19.
Sypniewski M, Król ZJ, Szyda J, Kaja E, Mroczek M, Suchocki T, Lejman A, Stępień M, Topolski P, Dąbrowski M, Kotlarz K, Aplas A, Wasiak M, Wojtaszewska M, Zawadzki P, Pawlak A, Gil R, Dobosz P, Stojak J. Sypniewski M, et al. Among authors: gil r. Int J Mol Sci. 2022 Aug 4;23(15):8696. doi: 10.3390/ijms23158696. Int J Mol Sci. 2022. PMID: 35955824 Free PMC article.
The study aims to check if any gene variants related to cardiovascular (CVD) and pulmonary diseases (PD) are correlated with a severe outcome of COVID-19 in a Polish cohort of COVID-19 patients. ...
The study aims to check if any gene variants related to cardiovascular (CVD) and pulmonary diseases (PD) are correlated with a severe …
185 results